-
公开(公告)号:US20080305151A1
公开(公告)日:2008-12-11
申请号:US12066849
申请日:2006-09-20
申请人: Yasushi Sakai , Masao Kimura , Shun Kayahashi , Toshikazu Kamiya , Shin-ichi Hashimoto , Hideo Kawabe
发明人: Yasushi Sakai , Masao Kimura , Shun Kayahashi , Toshikazu Kamiya , Shin-ichi Hashimoto , Hideo Kawabe
IPC分类号: A61K9/00 , C07C229/02 , A61K38/05
CPC分类号: A61K9/2095 , A23L2/39 , A23L33/18 , A23V2002/00 , A61K9/2018 , A61K9/2059 , A61K38/05 , A23V2200/316 , A23V2250/0628 , A23V2250/0654 , A23V2250/0626 , A23V2250/0604 , A23V2250/0622 , A23V2250/0606 , A23V2250/0642 , A23V2250/0608 , A23V2250/062
摘要: The present invention provides a composition for oral administration, which comprises at least one kind of dipeptide represented by the formula: X-Y (wherein X represents alanyl, glycyl, arginyl, seryl, α-aspartyl or α-glutamyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation and comprises at least one kind selected from valine, leucine and isoleucine, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property and comprises at least one kind selected from valine, leucine and isoleucine.
摘要翻译: 本发明提供了一种口服给药用组合物,其包含至少一种由下式表示的二肽:<?in-line-formula description =“In-line Formulas”end =“lead”?> XY < line-formula description =“In-line Formulas”end =“tail”?>(其中X表示丙氨酰,甘氨酰,精氨酰,丝氨酰,α-天冬氨酰或α-谷氨酰,Y表示缬氨酸,亮氨酸或异亮氨酸) 提供口服给药组合物的目的在营养,药理作用和阵风上优异,并且包含选自缬氨酸,亮氨酸和异亮氨酸的至少一种,或提供加工特性如溶解性和压片性优异的口服用组合物 性质并且包含选自缬氨酸,亮氨酸和异亮氨酸中的至少一种。
-
公开(公告)号:US20100311837A1
公开(公告)日:2010-12-09
申请号:US12866001
申请日:2009-02-05
申请人: Yasushi Sakai , Shun Kayahashi
发明人: Yasushi Sakai , Shun Kayahashi
IPC分类号: A61K31/195 , A61Q19/02 , A61Q19/08 , A61P3/10
CPC分类号: A61K31/198 , A23L33/10 , A23L33/175 , A23V2002/00 , A61K9/145 , A61K47/12 , A61K47/183 , A23V2200/02 , A23V2250/31 , A23V2250/0606 , A23V2250/063 , A23V2250/032 , A23V2250/056 , A23V2250/044 , A23V2250/708
摘要: The invention provides a method of improving the preservation stability of glutathione in a solid composition containing glutathione and arginine. In particular, glutathione and arginine are made to be coexistent with an organic acid such as citric acid, tartaric acid, ascorbic acid, malic acid, malonic acid, succinic acid, fumaric acid, maleic acid and the like. The amount of the organic acid to coexistent with glutathione and arginine is generally 0.1-2 parts by weight relative to 1 part by weight of arginine.
摘要翻译: 本发明提供一种改善含有谷胱甘肽和精氨酸的固体组合物中谷胱甘肽的保存稳定性的方法。 特别地,使谷胱甘肽和精氨酸与有机酸如柠檬酸,酒石酸,抗坏血酸,苹果酸,丙二酸,琥珀酸,富马酸,马来酸等共存。 与谷胱甘肽和精氨酸共存的有机酸的量通常相对于1重量份精氨酸为0.1-2重量份。
-
公开(公告)号:US07846902B2
公开(公告)日:2010-12-07
申请号:US12066849
申请日:2006-09-20
申请人: Yasushi Sakai , Masao Kimura , Shun Kayahashi , Toshikazu Kamiya , Shin-ichi Hashimoto , Hideo Kawabe
发明人: Yasushi Sakai , Masao Kimura , Shun Kayahashi , Toshikazu Kamiya , Shin-ichi Hashimoto , Hideo Kawabe
CPC分类号: A61K9/2095 , A23L2/39 , A23L33/18 , A23V2002/00 , A61K9/2018 , A61K9/2059 , A61K38/05 , A23V2200/316 , A23V2250/0628 , A23V2250/0654 , A23V2250/0626 , A23V2250/0604 , A23V2250/0622 , A23V2250/0606 , A23V2250/0642 , A23V2250/0608 , A23V2250/062
摘要: A composition for oral administration is provided, which includes at least one dipeptide represented by the formula: (wherein X represents alanyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property.
摘要翻译: 提供一种用于口服给药的组合物,其包括至少一种由下式表示的二肽(其中X表示丙氨酰,Y表示缬氨酸,亮氨酸或异亮氨酸),其目的是提供营养优异的口服组合物 ,药理作用和气味,或提供口服给药组合物,其加工特性如溶解度和压片性能优异。
-
公开(公告)号:US09918951B2
公开(公告)日:2018-03-20
申请号:US12866001
申请日:2009-02-05
申请人: Yasushi Sakai , Shun Kayahashi
发明人: Yasushi Sakai , Shun Kayahashi
IPC分类号: A61K9/00 , A61K31/198 , A61K9/14 , A61K47/12 , A61K47/18 , A23L33/10 , A23L33/175
CPC分类号: A61K31/198 , A23L33/10 , A23L33/175 , A23V2002/00 , A61K9/145 , A61K47/12 , A61K47/183 , A23V2200/02 , A23V2250/31 , A23V2250/0606 , A23V2250/063 , A23V2250/032 , A23V2250/056 , A23V2250/044 , A23V2250/708
摘要: The invention provides a method of improving the preservation stability of glutathione in a solid composition containing glutathione and arginine. In particular, glutathione and arginine are made to be coexistent with an organic acid such as citric acid, tartaric acid, ascorbic acid, malic acid, malonic acid, succinic acid, fumaric acid, maleic acid and the like. The amount of the organic acid to coexistent with glutathione and arginine is generally 0.1-2 parts by weight relative to 1 part by weight of arginine.
-
公开(公告)号:US07332522B2
公开(公告)日:2008-02-19
申请号:US10473867
申请日:2002-03-28
IPC分类号: A61K31/34 , A61K31/343
CPC分类号: A61K31/365 , A23L33/10 , A61K31/366 , C07D307/88 , C07D311/76
摘要: A liver function protecting or improving agent which comprises a compound represented by the formula (I) {in the formula (I), R1, R2, R3, R4, R5, R6, R7, R8 and R9 may be the same or different, and represent hydrogen, halogen, hydroxy, alkoxy or alkyl; and RA represents the formula (II) [in the formula (II), R10 and R11 may be the same or different, and represent hydrogen or halogen, or R10 and R11 together represent a binding] or the formula (III) [in the formula (III), R12 represents hydrogen, halogen, hydroxy, alkoxy, cyano or alkyl, R13 and R14 may be the same or different, and represent hydrogen or halogen, or R13 and R14 together represent a binding]} or a glycoside thereof or a pharmaceutically acceptable salt thereof.
摘要翻译: 一种肝功能保护或改善剂,其包含由式(I)表示的化合物(在式(I)中,R 1,R 2,R 2,R 2, R 4,R 4,R 5,R 6,R 7,R 7, 8和R 9可以相同或不同,表示氢,卤素,羟基,烷氧基或烷基; 并且R A表示式(II)[在式(II)中,R 10和R 11可以相同或不同, 并且表示氢或卤素,或者R 10和R 11一起代表结合]或式(III)[在式(III)中,R 12 代表氢,卤素,羟基,烷氧基,氰基或烷基,R 13和R 14可以相同或不同,表示氢或卤素,或 R 13和R 14一起代表其结合的}}或其糖苷或其药学上可接受的盐。
-
公开(公告)号:US20100040715A1
公开(公告)日:2010-02-18
申请号:US12519190
申请日:2007-12-14
申请人: Toshikazu Kamiya , Shun Kayahashi , Akio Shirai
发明人: Toshikazu Kamiya , Shun Kayahashi , Akio Shirai
IPC分类号: A61K36/00
CPC分类号: A61K36/07 , A61K31/198
摘要: The invention provides a composition containing a fruit body of Agaricus blazei murill or an extract of the fruit body, and an amino acid constituting the ornithine cycle or a salt thereof, wherein the pharmacological activities of the fruit body of Agaricus blazei murill or the extract of the fruit body and the amino acid constituting the omithine cycle or the salt thereof are increased synergistically. Such a composition can contain a fruit body of Agaricus blazei murill or an extract of the fruit body, and an amino acid constituting the ornithine cycle or a salt thereof in 10-100 parts by weight per 1 part by weight of the fruit body or the extract.
摘要翻译: 本发明提供一种含有姬松茸的水果体或果实的提取物的组合物和构成鸟氨酸循环的氨基酸或其盐,其中,姬松茸蕈果实果实的药理活性或提取物 水果体和构成奥米星循环的氨基酸或其盐的协同增加。 这种组合物可以含有10-100重量份的每1重量份水果体或果实体的水果体的果实体或果实的提取物,以及构成鸟氨酸循环的氨基酸或其盐 提取。
-
公开(公告)号:US08178105B2
公开(公告)日:2012-05-15
申请号:US12519190
申请日:2007-12-14
申请人: Toshikazu Kamiya , Shun Kayahashi , Akio Shirai
发明人: Toshikazu Kamiya , Shun Kayahashi , Akio Shirai
IPC分类号: A61K36/06
CPC分类号: A61K36/07 , A61K31/198
摘要: The invention provides a composition containing a fruit body of Agaricus blazei murill or an extract of the fruit body, and an amino acid constituting the ornithine cycle or a salt thereof, wherein the pharmacological activities of the fruit body of Agaricus blazei murill or the extract of the fruit body and the amino acid constituting the omithine cycle or the salt thereof are increased synergistically. Such a composition can contain a fruit body of Agaricus blazei murill or an extract of the fruit body, and an amino acid constituting the ornithine cycle or a salt thereof in 10-100 parts by weight per 1 part by weight of the fruit body or the extract.
摘要翻译: 本发明提供一种含有姬松茸的水果体或果实的提取物的组合物和构成鸟氨酸循环的氨基酸或其盐,其中,姬松茸蕈果实果实的药理活性或提取物 水果体和构成奥米星循环的氨基酸或其盐的协同增加。 这种组合物可以含有10-100重量份的每1重量份水果体或果实体的水果体的果实体或果实的提取物,以及构成鸟氨酸循环的氨基酸或其盐 提取。
-
-
-
-
-
-